July 25, 2019 10:05 AM EDTUpdated July 26, 02:38 PM
News Briefing

ICER backs cost-ef­fec­tive­ness of Vas­cepa, Xarel­to; Epizyme's lead drug wins speedy US re­view

Natalie Grover

Reporter

→ Drug cost-ef­fec­tive­ness watch­dog ICER on Wednes­day un­veiled pre­lim­i­nary find­ings from its draft re­port on ad­di­tive car­dio­vas­cu­lar dis­ease ther­a­pies: Amarin’s $AM­RN fish oil pill …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

US spent $450B on drugs last year, CMS says, with new obe­si­ty and di­a­betes drugs adding to to­tal

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

A service from the Financial Times